ClinicalTrials.gg
RecruitingNCT06960213STOP-HAEUpdated Sep 10, 2026

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

A Phase 3 interventional study of ADX-324 and Placebo in Hereditary Angioedema, HAE and Hereditary Angioedema - Type 1, sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 70 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by ADARx Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Planned enrollment
25th of 74
90 · median 57
Started
2025
with 11 others
Phase 3
38 of 84
6 open now
Primary completion
2027-11
later than 8 of 17 live
Registered
75th of 84
by date
Lead sponsor
2 of 84
ADARx Pharmaceuticals, Inc.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 25th largest by planned enrollment of the 74 interventional ones that give a count, is one of 12 that started in 2025, is one of 38 in phase 3, reaches primary completion later than 8 of the 17 other live ones, and was the 75th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.

03

Conditions studied

  • Hereditary Angioedema
  • HAE
  • Hereditary Angioedema - Type 1
  • Hereditary Angioedema - Type 2

Keywords

  • HAE
  • Hereditary angioedema
  • onvuzosiran
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥18 years at the time of signing .
  • Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)
  • Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening
  • Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)

Key Exclusion Criteria:

  • Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).
  • Any renal disease
  • Any clinically significant hepatic disease
  • Have used any of the following for long-term prevention of HAE attacks:

    1. C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.
    2. Berotralstat (ORLADEYO) within 3 weeks prior to Screening.
    3. Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.
    4. Androgen use within 12 weeks prior to Screening.
  • Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    ADX-324 Dose Level 1

    Drug: ADX-324

  • Experimental
    ADX-324 Dose Level 2

    Drug: ADX-324

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • siRNA duplex oligonucleotide

    Also known as: siRNA

  • DrugPlacebo

    saline

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Efficacy of ADX-324 in preventing HAE attacks

    The time-normalized number of Investigator-confirmed HAE attacks per month for ADX-324 Dose Level 1 vs placebo

    Time frame: Day 22 to Week 25

Secondary outcomes

  1. Efficacy of ADX-324 in preventing HAE attacks

    The time-normalized number of Investigator-confirmed HAE attacks per month for ADX-324 Dose Level 2 vs placebo

    Time frame: Day 22 to Week 25

  2. Evaluate the effects of ADX-324 on the quality and pattern of HAE attacks

    The time-normalized number of Investigator-confirmed HAE attacks requiring acute HAE therapy per month for ADX-324 vs placebo.

    Time frame: Day 22 to Week 25

  3. Evaluate the effects of ADX-324 on the quality and pattern of HAE attacks

    The time-normalized number of moderate or severe Investigator confirmed HAE attacks per month for ADX 324 vs placebo.

    Time frame: Day 22 to Week 25

  4. Evaluate the effects of ADX-324 on the quality and pattern of HAE attacks

    The proportion of participants who have not experienced an Investigator-confirmed HAE attack (HAE attack-free) for ADX 324 vs placebo.

    Time frame: Day 22 to Week 25

  5. Evaluate the effects of ADX-324 on the quality and pattern of HAE attacks

    The proportion of participants with a clinical response defined as a ≥50%, ≥70%, or ≥90% reduction from baseline in Investigator-confirmed HAE attack rate for ADX 324 vs placebo.

    Time frame: Day 22 to Week 25

07

Study locations

52 of 70 sites recruiting
  • ADARx Clinical Site
    Litchfield Park, Arizona 85340, United States
    Recruiting
  • ADARx Clinical Site
    Scottsdale, Arizona 85251, United States
    Recruiting
  • ADARx Clinical Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • ADARx Clinical Site
    San Diego, California 92122, United States
    Recruiting
  • ADARx Clinical Site
    Santa Monica, California 90404, United States
    Not yet recruiting
  • ADARx Clinical Site
    Walnut Creek, California 94598, United States
    Recruiting
  • ADARx Clinical Site
    Centennial, Colorado 80112, United States
    Recruiting
  • ADARx Clinical Site
    Orlando, Florida 32807, United States
    Recruiting
  • ADARx Clinical Site
    Chevy Chase, Maryland 20815, United States
    Recruiting
  • ADARx Clinical Site
    Wheaton, Maryland 20902, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • ADARx Clinical Site
    Detroit, Michigan 48202, United States
    Recruiting
  • ADARx Clinical Site
    St Louis, Missouri 63141, United States
    Recruiting
  • ADARx Clinical Site
    Las Vegas, Nevada 89128, United States
    Recruiting
  • ADARx Clinical Site
    New York, New York 10029, United States
    Recruiting
  • ADARx Clinical Site
    Cincinnati, Ohio 45236, United States
    Recruiting
  • ADARx Clinical Site
    Cleveland, Ohio 44195, United States
    Not yet recruiting
  • ADARx Clinical Site
    Columbus, Ohio 43235, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • ADARx Clinical Site
    Toledo, Ohio 43617, United States
    Recruiting
  • ADARx Clinical Site
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • ADARx Clinical Site
    Capital Federal, Buenos Aires C1425BEN, Argentina
    Recruiting
  • ADARx Clinical Site
    Buenos Aires, Buenos Aires F.D. C1035AAT, Argentina
    Recruiting
  • ADARx Clinical Site
    Pilar, 1629, Argentina
    Recruiting
  • ADARx Clinical Site
    Rosario, 2000, Argentina
    Recruiting
  • ADARx Clinical Site
    Campbelltown, New South Wales 2560, Australia
    Not yet recruiting
  • ADARx Clinical Site
    Adelaide, South Australia 5000, Australia
    Recruiting
  • ADARx Clinical Site
    Vienna, 1090, Austria
    Recruiting
  • ADARx Clinical Site
    Edegem, Antwerpen 2650, Belgium
    Recruiting
  • ADARx Clinical Site
    Campinas, 13073-002, Brazil
    Not yet recruiting
  • ADARx Clinical Site
    São Paulo, 01246-903, Brazil
    Not yet recruiting
  • ADARx Clinical Site
    Sofia, 1000, Bulgaria
    Recruiting
  • ADARx Clinical Site
    Edmonton, Alberta T6G 2R3, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • ADARx Clinical Site
    Edmonton, Alberta T6G 2R3, Canada
    Not yet recruiting
  • ADARx Clinical Site
    Ottawa, Ontario K1H 1E4, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • ADARx Clinical Site
    Montreal, Quebec H2W 1R7, Canada
    Recruiting
  • ADARx Clinical Site
    Beijing, 100730, China
    Recruiting
  • ADARx Clinical Site
    Harbin, 150001, China
    Not yet recruiting
  • ADARx Clinical Site
    Zhengzhou, 450003, China
    Not yet recruiting
  • ADARx Clinical Site
    Split, 21000, Croatia
    Recruiting
  • ADARx Clinical Site
    Zagreb, 10000, Croatia
    Recruiting
  • ADARx Clinical Site
    Hradec Králové, 500 05, Czechia
    Recruiting
  • ADARx Clinical Site
    Prague, 15000, Czechia
    Recruiting
  • ADARx Clinical Site
    Nice, Alpes-Maritimes 06300, France
    Recruiting
  • ADARx Clinical Site
    Tours, Indre-et-Loire 37000, France
    Recruiting
  • ADARx Clinical Site
    Grenoble, 38043, France
    Recruiting
  • ADARx Clinical Site
    Montpellier, 34295, France
    Recruiting
  • ADARx Clinical Site
    Paris, 75012, France
    Recruiting
  • ADARx Clinical Site
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
  • ADARx Clinical Site
    Hong Kong, 111, Hong Kong
    Recruiting
  • ADARx Clinical Site
    Budapest, 1088, Hungary
    Recruiting
  • ADARx Clinical Site
    Ramat Gan, Tel Aviv 5262100, Israel
    Recruiting
  • ADARx Clinical Site
    Ashkelon, 7830604, Israel
    Recruiting
  • ADARx Clinical Site
    Tel Aviv, 64239, Israel
    Recruiting
  • ADARx Clinical Site
    Palermo, 90100, Italy
    Recruiting
  • ADARx Clinical Site
    Krakow, Poland
    Recruiting
  • ADARx Clinical Site
    Lodz, 92-213, Poland
    Recruiting
  • ADARx Clinical Site
    Wroclaw, 50-556, Poland
    Recruiting
  • ADARx Clinical Site
    Belgrade, 11000, Serbia
    Recruiting
  • ADARx Clinical Site
    Mowbray, Capetown 7700, South Africa
    Not yet recruiting
  • ADARx Clinical Site
    Barcelona, 08907, Spain
    Recruiting
  • ADARx Clinical Site
    Madrid, 28007, Spain
    Recruiting
  • ADARx Clinical Site
    Taichung, 40705, Taiwan
    Recruiting
  • ADARx Clinical Site
    Ankara, 06100, Turkey (Türkiye)
    Not yet recruiting
  • ADARx Clinical Site
    Bornova, 35100, Turkey (Türkiye)
    Not yet recruiting
  • ADARx Clinical Site
    Istanbul, 34093, Turkey (Türkiye)
    Not yet recruiting
  • ADARx Clinical Site
    Kayseri, 38039, Turkey (Türkiye)
    Not yet recruiting
  • ADARx Clinical Site
    Guildford, Surrey GU2 7XX, United Kingdom
    Not yet recruiting
  • ADARx Clinical Site
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • ADARx Clinical Site
    Cardiff, CF14 4YS, United Kingdom
    Recruiting
  • ADARx Clinical Site
    London, E1 1BB, United Kingdom
    Recruiting
  • ADARx Clinical Site
    Southampton, SO16 6YD, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 27 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 27 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
May 7, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06960213
Lead sponsor
ADARx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 7, 2025
Start date
Aug 28, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Lupe Gallegos
Contact
info@adarx.com
877-232-7974
Lauge Farnaes, MD
study director · ADARx Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onvuzosiran sodium

Start the discussion